SCHEMBL3264784

SCHEMBL3264784

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(-c4cccc(Br)c4)cs3)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.49
ALDH1A1 P00352 6/20 0.49
LMNA P02545 6/20 0.49
HSD17B10 Q99714 4/20 0.49
MAPK1 P28482 3/20 0.49
TP53 P04637 2/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
TSHR P16473 1/20 0.49
SMN1; SMN2 Q16637 9/20 0.48
RAB9A P51151 3/20 0.48
HTT P42858 4/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
MMP2 P08253 1/20 0.45
MMP8 P22894 1/20 0.45
NPC1 O15118 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012428 0.94 SMN1; SMN2 (0.46) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3004551 0.93 MAPT (0.49) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3019369 0.93 MAPT (0.53) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3012571 0.93 MAPT (0.56) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3020124 0.91 SMN1; SMN2 (0.51) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3008718 0.90 MAPT (0.49) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3014509 0.90 MAPT (0.57) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3021012 0.89 SMN1; SMN2 (0.57) MAPTALDH1A1LMNAMAPK1TP53
SCHEMBL3007426 0.88 SMN1; SMN2 (0.58) MAPTALDH1A1LMNAHSD17B10MAPK1
SCHEMBL3002190 0.88 SMN1; SMN2 (0.61) MAPTALDH1A1LMNAHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.